Head-to-head evidence
Aripiprazole (Abilify) vs Aripiprazole lauroxil (Aristada)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 and serotonin 5-HT1A receptor · full Schizophrenia pipeline
Aripiprazole (Abilify)
Marketed by Otsuka Holdings and partners
NCT00712686 · Phase 3 · completed
The study was a large randomized, double-blind, active-controlled trial comparing aripiprazole with olanzapine, with 690 participants. However, the registry provides no results for either primary endpoint, so it is not possible to determine whether the primary comparisons were favorable or statistically significant.
Next expected readout: September 2027 · NCT07547384 (registry estimate)
Aripiprazole lauroxil (Aristada)
Marketed by Alkermes plc
NCT01469039 · Phase 3 · completed
The trial was randomized, quadruple-blinded, and placebo-controlled, with 623 participants assigned to aripiprazole lauroxil 441 mg, 882 mg, or placebo. Its primary clinical symptom endpoint, change in PANSS total score at day 85, was significantly better with both active doses than with placebo (p<0.001 for each comparison).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aripiprazole (Abilify)'s landscape · Aripiprazole lauroxil (Aristada)'s landscape